A metabolomics signature on liquid biopsy as a prognostic and predictive biomarker in early breast cancer

We will compare the metabolomics profile of large cohorts of breast cancer patients with documented treatment outcome in order to identify candidate biomarkers of treatment response or recurrence risk. Such identification fo non-responder patients and of patients at risk of relapse could help define those patients likely to benefit from neoadjuvant escalation treatment and those who might benefit from de-escalation strategies.